scholarly article | Q13442814 |
P356 | DOI | 10.2337/DC18-0623 |
P698 | PubMed publication ID | 30026335 |
P50 | author | Paresh Dandona | Q29447364 |
Pieter Gillard | Q56811703 | ||
Serge Jabbour | Q87858486 | ||
Chantal Mathieu | Q88112330 | ||
Marcus Lind | Q89461797 | ||
P2093 | author name string | Peter Senior | |
Lars Hansen | |||
Eiichi Araki | |||
Niki Arya | |||
Christoph Hasslacher | |||
Stephen C Bain | |||
Anna Maria Langkilde | |||
Fredrik Thorén | |||
DEPICT-2 Investigators | |||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | type-1 diabetes | Q124407 |
P304 | page(s) | 1938-1946 | |
P577 | publication date | 2018-07-19 | |
P1433 | published in | Diabetes Care | Q5270111 |
P1476 | title | Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial | |
P478 | volume | 41 |
Q90043452 | Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update |
Q64231829 | Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment |
Q97682132 | Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes |
Q64767149 | Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus |
Q57822742 | Developments in the Management of Type 1 and Type 2 Diabetes |
Q90398929 | Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes |
Q99569227 | Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials |
Q93030859 | Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials |
Q92583713 | Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial |
Q64904716 | Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy. |
Q92304196 | Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care |
Q92964215 | HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study |
Q92126784 | Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program |
Q64385669 | International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors |
Q92139553 | Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy |
Q92737259 | Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM |
Q64780233 | Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus |
Q93130541 | NICE guidance on dapagliflozin with insulin for type 1 diabetes |
Q91778233 | Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes |
Q91984134 | Past, present and future of latent autoimmune diabetes in adults |
Q93382017 | Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes |
Q89465090 | Renal physiology of glucose handling and therapeutic implications |
Q93221847 | Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes |
Q98386639 | SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects |
Q90491155 | SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks |
Q91970275 | Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials |
Q89890479 | Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study |
Q92117496 | Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes |
Q91977138 | Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption |
Q89499060 | The mechanism of hsa-miR-424-5 combining PD-1 through mTORC signaling pathway to stimulate immune effect and participate in Type 1 diabetes |
Q64816409 | Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus |
Search more.